X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (106) 106
index medicus (96) 96
oncology (76) 76
male (71) 71
female (69) 69
middle aged (67) 67
life sciences (62) 62
chemotherapy (56) 56
respiratory system (56) 56
aged (55) 55
cancer (52) 52
lung cancer (49) 49
santé publique et épidémiologie (46) 46
lung neoplasms - drug therapy (42) 42
lung cancer, non-small cell (41) 41
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (38) 38
adult (37) 37
carcinoma, non-small-cell lung - drug therapy (36) 36
lung neoplasms - pathology (36) 36
care and treatment (34) 34
carcinoma, non-small-cell lung - pathology (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
neoplasm staging (28) 28
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (27) 27
analysis (26) 26
mesh: humans (26) 26
france (25) 25
research (24) 24
lung neoplasms - mortality (23) 23
treatment outcome (23) 23
metastasis (22) 22
aged, 80 and over (21) 21
carcinoma, non-small-cell lung - mortality (21) 21
hematology, oncology and palliative medicine (21) 21
pulmonary/respiratory (21) 21
mesh: middle aged (20) 20
survival (20) 20
prognosis (19) 19
chronic obstructive pulmonary disease (18) 18
management (18) 18
mesh: male (18) 18
non-small cell lung cancer (18) 18
trial (18) 18
cisplatin (17) 17
lung neoplasms (17) 17
mesh : humans (17) 17
mesh: female (17) 17
patients (17) 17
cancer therapies (16) 16
cisplatin - administration & dosage (16) 16
docetaxel (16) 16
france - epidemiology (16) 16
medicine (16) 16
nsclc (16) 16
studies (16) 16
lung neoplasms - therapy (15) 15
mortality (15) 15
pemetrexed (15) 15
prospective studies (15) 15
therapy (15) 15
antineoplastic agents - therapeutic use (14) 14
carcinoma, non-small-cell lung - therapy (14) 14
cost-effectiveness (14) 14
erlotinib (14) 14
lung neoplasms - economics (14) 14
mesh: adult (14) 14
non-small-cell lung cancer (14) 14
oncology, experimental (14) 14
quality of life (14) 14
risk factors (14) 14
antineoplastic agents (13) 13
disease-free survival (13) 13
immunotherapy (13) 13
lung diseases, obstructive (13) 13
mesh : middle aged (13) 13
mesh: aged (13) 13
research article (13) 13
survival rate (13) 13
carcinoma, non-small-cell lung - economics (12) 12
cost analysis (12) 12
development and progression (12) 12
diagnosis (12) 12
follow-up studies (12) 12
gemcitabine (12) 12
medicine & public health (12) 12
mesh : male (12) 12
mesh: lung neoplasms (12) 12
mutation (12) 12
retrospective studies (12) 12
survival analysis (12) 12
bevacizumab (11) 11
carcinoma, non-small-cell lung (11) 11
copd (11) 11
cost-benefit analysis (11) 11
deoxycytidine - analogs & derivatives (11) 11
economic aspects (11) 11
guanine - analogs & derivatives (11) 11
mesh : female (11) 11
respiratory tract diseases (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0182798
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
Expert review of pharmacoeconomics & outcomes research, 10/2018, Volume 18, Issue 5, p. 519
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
The Journal of Allergy and Clinical Immunology: In Practice, ISSN 2213-2198, 05/2019, Volume 7, Issue 5, pp. 1477 - 1487
Journal Article
ClinicoEconomics and Outcomes Research, ISSN 1178-6981, 12/2014, Volume 7, pp. 9 - 15
During these last years, there have been an increased number of new drugs for non-small cell lung cancer (NSCLC), with a growing financial effect on patients... 
Economics | Evaluation | Costs | Cost-effectiveness | Lung cancer | Economic aspects | Lung cancer, Small cell | Chemotherapy | Lymphomas | Lung cancer, Non-small cell | Cancer | Health care policy | Cost reduction | Histology | Metastasis | Patients | Cancer therapies | Cost control | Pharmacoeconomics | Mutation | Cost analysis | Maintenance management
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0121539
Journal Article